Elan beefs up its US bid defences

James Ashton
May 2013
Evening Standard;5/20/2013, p41
DRUGMAKER Elan today announced its second major drug deal in days and launched a share buyback scheme as it protects itself from a $5.7 billion (£3.7 billion) bid from Royalty Pharma of the US. The Irish medicine-maker announced a €263.5 million (£223 million) deal to buy Austrian rare drug specialist AOP Orphan and is paying $40 million for a stake in a Dubai pharma firm.


Related Articles

  • Perrigo Seeks Tax Advantages with Elan Acquisition. Cartwright, Heather // PharmaDeals Review;2013, Vol. 2013 Issue 8, p79 

    In order to reduce its tax bill, OTC drug maker Perrigo has agreed to acquire Ireland-based Elan for approximately US$8.6 B, or US$6.7 B net of cash on hand. Elan's principal asset is a tiered doubledigit royalty stream on sales of the multiple sclerosis drug Tysabri® (natalizumab), which it...

  • Shire stands up to £27bn AbbVie bid. Rob Davies // Daily Mail;6/23/2014, p57 

    DRUGS firm Shire will today step up its defence against the £27bn takeover bid by US rival AbbVie in a charm offensive aimed at shareholders anticipating an improved offer.

  • Royalty Pharma Increases Its Bid for Elan to $7.3B. Sheridan, Cormac // BioWorld International;4/17/2013, Vol. 18 Issue 16, p1 

    The article reports that Royalty Pharma increased its bid for biotechnology firm Elan Corp. plc to 12 U.S. dollars per share. The increased offer follows a general meeting held by Elan in Dublin, Germany, at which shareholders approved a one billion U.S. dollar share buyback. The author also...

  • Elan Looks East with 2 Deals As Royalty Revises Hostile Bid. Sheridan, Cormac // BioWorld International;5/22/2013, Vol. 18 Issue 21, p1 

    The article reports that Irish drug company Elan Corp. PLC is continuing its merger and acquisition (M&A) strategy despite facing a hostile bid from Royalty Pharma. Elan is buying AOP Pharmaceuticals AG and is also planning to acquire a stake in Newbridge Pharmaceuticals FZ-LLC. Royalty Pharma...

  • Elan Faces Hostile Bid from Royalty Pharma.  // MondayMorning;4/22/2013, Vol. 21 Issue 15, p1 

    The article focuses on takeover bidding offer from Royalty Pharma AG, an investor in royalty streams from pharmaceuticals, to buy Elan Corp. PLC. It mentions that Royalty Pharma has raised its offer to U.S. dollars 7.3 billion. It mentions shareholders of Elan Corp. PLC will be enable to avoid...

  • Rolls takes two on board and eyes progress. Nick Goodway // Evening Standard;11/ 8/2013, p57 

    ROLLS-ROYCE beefed up its board and raised its forecasts for its defence business today, propelling its shares up by more than 4%.

  • Elan's Woes Continue. Houlton, Sarah // Pharmaceutical Executive;Aug2003, Vol. 23 Issue 8, p18 

    Reports on the decline of the shares of Elan Corp. in the U.S. Technical default faced by Elan on its debt covenants; Sale of the assets of Elan; Use of the proceeds to repay its debt.

  • Elan to Sell Anti-Fungal Drug to Enzon for $370 Million.  // Chemical Market Reporter;10/7/2002, Vol. 262 Issue 12, p4 

    Reports that U.S. -based Elan Corp. has sell its rights to Enzon Inc. for 370 million dollar for an antifungal drug called Abelcet. Increase in the share price of Elan; Revenue generated by Elan in the year 2001; Decrease in research expenditures; Improvement in the liquidity of Elan.

  • California Pizza Kitchen Seeks Takeout.  // Mergers & Acquisitions Report;6/7/2010, Vol. 23 Issue 23, p33 

    This section offers news briefs on the mergers and acquisitions (M&A) market in the U.S. Moelis & Co. was hired by California Pizza Kitchen to serve as its advisor in reviewing possible financial and strategic alternatives. Qwest Communications was acquired by CenturyTel Inc. in an all-stock...

  • Czech, US, German firms bidding for Slovenian sports goods manufacturer.  // Regional Today;11/13/2014, p2 

    The article reports that Czech ski manufacturer Sporten, U.S. company Boba Ing, and other media companies will be bidding for Slovakian sports manufacturer Elan.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics